Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs adalimumab for anxiety in psoriatic arthritis
ChiCTR2400079755Phase 4Recruiting
- Sponsor
- Shenzhen Traditional Chinese Medicine Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of upadacitinib in psoriatic arthritis (PsA) and anxiety disorder (2 arms), sponsored by Shenzhen Traditional Chinese Medicine Hospital. Primary endpoint: Hospital Anxiety Self-Assessment Scale (HADS-A). Started Jan 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2400079755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079755.